Tunisian economy records annual growth driven by agricultural sector
The Tunisian economy grew by 1.6% year-on-year in the first quarter of 2025, supported by the agricultural sector, according to data released on Thursday by the National Institute of Statistics (INS) in Tunisia.
This growth is attributed to the positive performance of the agricultural sector, which contributed 0.59% to the overall GDP growth, alongside a 0.5% increase in industrial output compared to the first quarter of 2024.
On a quarterly basis, however, Tunisia's economic growth declined by 0.2% in Q1 2025 compared to the last quarter of 2024, as per the institute's data.
Unemployment in Tunisia dropped to 15.7% in the first quarter of 2025, down from 16% in the previous recorded figure from Q3 2024. According to the same data, youth unemployment (ages 15–24) fell to 37.7% from 40.5% in Q3 2024. Unemployment among university graduates also decreased to 23.5%, down from 25% in the same period.
This month, the Tunisian government pledged to resume hiring in the public sector, which had been suspended since 2017 due to fiscal constraints. Minister of Employment and Vocational Training, Riyadh Chaoud, stated that the 2025 budget includes around 20,000 job opportunities in public administration and state-owned enterprises.
Whatsapp Telegram Email Print
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
This Offering Will Not Dilute Quantum BioPharma Shareholders TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ('Quantum BioPharma'), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced that Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms – today announced the launch of its previously announced Regulation D 506(c) offering to raise up to US$5.0 million to fund growth and establish a path to a possible initial public offering. This will not impact or dilute Quantum BioPharma shareholders. Quantum BioPharma maintains an anti-dilution provision which ensures its ownership in Unbuzzd Wellness Inc. is 25% until unbuzzd reaches $1,000,000,000 (One Billion US Dollars) in valuation. Once Unbuzzd Wellness Inc. goes public, Quantum BioPharma will be able to access non-dilutive capital through its ownership. Unbuzzd has partnered with MZ Digital, a global leader in marketing, and Dealmaker, a leading online platform for raising capital to conduct the capital raise campaign. The Regulation D offering allows Unbuzzd to raise capital by selling and issuing securities to accredited investors without a cap on the amount raised. Investments can be made with traditional payments or with cryptocurrency payments: the latter through ALT5 Pay's digital payments platform. To learn more about the offering and invest, visit this link Unbuzzd Invest. John Duffy, CEO of Unbuzzd Wellness, stated, "This capital raise allows us to introduce investors to a new era in functional beverages aimed at supporting overall wellness after social occasions. unbuzzd is a refreshing, science-backed beverage that helps people feel more refreshed and alert after drinking. This offering will help us raise the necessary capital to support direct-to-consumer, distributor, and retail expansion plans.' Mr. Duffy has over twenty years of leadership experience in the beverage industry, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola. Gerry David, Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, "Together with our partners MZ Digital, a global leader in online marketing, and Dealmaker, a leading online platform for raising capital, we are excited to launch this offering to build our company and sales momentum, and position Unbuzzd for a future initial public offering." About Quantum BioPharma Ltd. Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ('Lucid'), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of 20.11% (as of March 31, 2025) of Unbuzzd Wellness Inc. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information on Quantum BioPharma, please visit About Unbuzzd Wellness Inc. Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day. Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration ("BAC"), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include: Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects. Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results. Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant. Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication. Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd. No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects. The full press release of the clinical trial can be found here. unbuzzd ready-to-mix powder sticks are available in 3-pack and 18-pack formats at unbuzzdTM is a registered trademark of Unbuzzd Wellness Inc. Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE. For more information on Unbuzzd Wellness Inc. please visit 18-pack, and 3-pack formats of the unbuzzd ready-to-mix powder sticks Forward-Looking Information Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such. Forward-looking information in this press release are based on certain assumptions and expected future events. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at and on the EDGAR section of the United States Securities and Exchange Commission's website at for a more complete discussion of such risk factors and their potential effects. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. Contacts: Quantum BioPharma Saeed, Founder, CEO and Executive Co-Chairman of the BoardEmail: Zsaeed@ (833) 571-1811 Investor RelationsInvestor Relations: IR@ Inquiries: info@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Jury retires in trial of man accused of murdering ex-fiancee at luxury hotel
A jury has retired to consider its verdicts in the trial of a 61-year-old man accused of murdering his ex-fiancee at a luxury hotel in Surrey. Samantha Mickleburgh was found dead at the Pennyhill Park Hotel in Bagshot on the morning of April 14 last year. The mother-of-two, 54, had arranged to stay in a twin room with her ex-fiance, James Cartwright, the night before, because she 'didn't want him to feel lonely' on his birthday, his trial at Guildford Crown Court previously heard. Cartwright called 999 just before 8.30am on April 14 claiming he had discovered the lifeless body of Ms Mickleburgh lying next to him in bed. The defendant, of no fixed address, is accused of raping and murdering Ms Mickleburgh between April 12 and April 14 last year, which he denies. He also denies one count of controlling and coercive behaviour between May 1 2022 and April 14, a father-of-three, previously told jurors his ex-fiancee owed him about £100,000 at the time of her death as Ms Mickleburgh, from Axminster in Devon, borrowed money to help renovate a property she bought in early 2023. The pair lived together and got engaged later that year, with Cartwright proposing on a beach during a holiday, the court previously heard. But the relationship began to break down when Cartwright discovered 'highly sexual' messages from Ms Mickleburgh's former partner on her phone and later on her laptop, the jury has been told. Prosecutors allege Cartwright was leading a double life, and the court heard the 61-year-old had been dancing at a ceilidh with his new girlfriend the night before he allegedly killed Ms Mickleburgh. The jury retired at 12.26pm on Thursday.
Yahoo
5 minutes ago
- Yahoo
Acadian Asset Management Inc. Reports Financial and Operating Results for the Second Quarter Ended June 30, 2025
BOSTON, July 31, 2025--(BUSINESS WIRE)--Acadian Asset Management Inc. (NYSE: AAMI) today announced its results for the second quarter ended June 30, 2025. Acadian Asset Management Inc.'s earnings presentation is available at: The Company will hold a conference call and simultaneous webcast to discuss the results at 11:00 a.m. Eastern Time today. To listen to the call or view the webcast, participants should: Dial-in Toll Free Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307-1963 Conference ID: 9046067 Visit for the webcast link (register ahead of time or join immediately prior to the call). A replay of the call will be available beginning approximately one hour after its conclusion either on Acadian Asset Management Inc.'s website, at or by: Dial-in Replay Toll Free Dial-in Number: (800) 770-2030 International Dial-in Number: (609) 800-9909 Conference ID: 9046067 About Acadian Asset Management Inc. Acadian Asset Management Inc. is the NYSE listed holding company of Acadian Asset Management LLC, with approximately $151 billion of assets under management as of June 30, 2025. Acadian offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives. For more information, please visit the Company's website at Information that may be important to investors will be routinely posted on our website. View source version on Contacts Investor Relationsir@ (617) 369-7300 Sign in to access your portfolio
